Loading organizations...
Pacific Ventures Group operates as an investment firm dedicated to the consumer products sector, with a specific emphasis on the food, beverage, and alcohol industries. The group provides capital and strategic support to companies ranging from early-stage startups to those in expansion phases, aiming to foster growth and market penetration. Its approach involves partnering with promising businesses to enhance their operational capabilities and market reach within these specialized consumer verticals.
The firm was founded by Ralph Sabin, who identified significant opportunities within the evolving consumer landscape of food, beverage, and alcohol. This foundational insight drove the establishment of Pacific Ventures Group as a targeted investment vehicle designed to capitalize on and contribute to the development of these industries. Sabin’s vision was to create a platform that could nurture emerging brands and technologies in this niche.
Pacific Ventures Group primarily serves businesses operating within the food, beverage, and alcohol consumer product categories, acting as a strategic partner to accelerate their development. The company's overarching vision is to become the preferred investment partner for innovative brands in these sectors, supporting their journey from nascent stages to full market potential and sustained success.
Pacific Venture Group has 2 tracked investments across 1 company. The latest tracked deal is $20.0M Other Equity in Nereus Pharmaceuticals in June 2010.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 23, 2010 | Nereus Pharmaceuticals | $20.0M Other Equity | HBM Healthcare Investments | Advent International, Alta Partners, Astellas Venture Management, Forward Ventures, GIMV, Roche |
| Aug 9, 2007 | Nereus Pharmaceuticals | $45.0M Series D | Bankinvest Biomedical Venture | Advent International, Alta Partners, Astellas Venture Management, Boston Life Science Venture Corporation, Eminent II Venture Capital, Forward Ventures, GIMV, HBM Healthcare Investments, Interwest Partners, Roche, Taiwan Global Biofund |